Getting vaccinated against shingles could play a meaningful role in healthy aging and may lower the risk of cognitive decline. This insight comes from research published in NPJ Vaccines.
Shingles results when the varicella zoster virus reactivates after the immune system weakens. It is a painful condition that can lead to complications such as hearing and vision issues, and has been linked to higher risks of stroke and heart attack. In the United States alone, more than a million shingles cases occur each year, and women appear to be affected more often. Vaccination can prevent shingles and its complications, a consideration of growing importance as populations age in many countries.
Today there are two vaccines approved to prevent shingles: a live vaccine made from a weakened form of the virus and a recombinant two-dose vaccine. The recombinant option tends to offer stronger protection for individuals with weakened immunity, including older adults who may be more susceptible to shingles and its complications.
Across studies, shingles vaccination has consistently reduced the severity of pain for those who still develop the condition. In some research, a substantial portion of patients reported severe pain, underscoring the burden of the illness. The recombinant vaccine not only lowers the likelihood of developing herpes zoster but also decreases the need for pain medications, reduces pain intensity, and lowers hospitalization rates among those who become ill. Emerging evidence also links shingles vaccination to a lower risk of dementia, prompting experts to advocate for broad vaccination programs in adults as a public health measure. (NPJ Vaccines study, attribution to researchers in NPJ Vaccines)
Since the aging population is growing in North America, preventive vaccination becomes a practical strategy for safeguarding long-term health. Preventing shingles also helps reduce the emotional and financial strain associated with managing severe pain and related health events. Health authorities in the United States and Canada emphasize shingles vaccination as part of routine preventive care for adults, particularly those over 50 or with risk factors for immune compromise. (Cited in contemporary vaccination guidelines)
Researchers note that the collective goal is to minimize the burden of herpes zoster while supporting overall well-being in older adults. By lowering rates of shingles and its complications, vaccines may contribute to healthier aging trajectories and, potentially, to reduced rates of dementia in the population. Ongoing studies continue to refine our understanding of these relationships and to inform vaccination strategies that maximize protection across diverse communities. (Clinical research notes and public health commentary)
In practice, individuals considering shingles vaccination should discuss options with a healthcare provider, especially those with weakened immune systems or chronic health conditions. The choice between vaccine types can depend on age, immune status, and personal health history. Completing the recommended two-dose schedule for the recombinant vaccine offers the strongest protection and aligns with current guidelines in North American health systems. Regular updates from health agencies help residents stay informed about eligibility, timing, and potential side effects. (Public health guidance)